Updates are available Correction dated 2021-11-16
Click to view Correction: https://doi.org/10.1038/s41375-021-01357-4
-
Authors
Mai, Elias K. http://orcid.org/0000-0002-6226-1252
Miah, Kaya
Bertsch, Uta
Dürig, Jan
Scheid, Christof
Weisel, Katja C.
Kunz, Christina
Munder, Markus
Lindemann, Hans-Walter
Merz, Maximilian
Hose, Dirk
Jauch, Anna
Seckinger, Anja
Luntz, Steffen
Sauer, Sandra
Fuhrmann, Stephan
Brossart, Peter
Elmaagacli, Ahmet
Goerner, Martin
Bernhard, Helga
Hoffmann, Martin
Raab, Marc S.
Blau, Igor W.
Hänel, Mathias
Benner, Axel http://orcid.org/0000-0002-7238-6956
Salwender, Hans J.
Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
,
-
Funding
Funding for this research was provided by:
Celgene (N/A)
F. Hoffmann-La Roche Ltd | Chugai Pharmaceutical (N/A)
Janssen Pharmaceuticals (N/A)
- License Information
-
More Information
Article History
Received: 29 March 2020
Revised: 29 June 2020
Accepted: 6 July 2020
First Online: 20 July 2020
Change Date: 16 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01357-4
Compliance with ethical standards
:
: EKM: honoraria: Janssen, Celgene, Takeda; consulting or advisory role: Janssen, Celgene, Takeda; research funding: Takeda; travel, accommodations, expenses: Janssen, Takeda, Celgene, Onyx, Mundipharma. KM: no COI. UB: travel, accommodations, expenses: Sanofi. JD: consulting or advisory role: Celgene; speakers bureau: Celgene; travel, accommodations, expenses: Celgene. CS: honoraria: BMS, Janssen, Celgene, Novartis, Amgen, Takeda; consulting or advisory role: BMS, Janssen, Celgene, Novartis, Amgen, Takeda; speakers bureau: Takeda; research funding: Takeda, Novartis; travel, accommodations, expenses: BMS, Janssen, Celgene, Novartis, Amgen, Takeda. KCW: honoraria: AMGEN, BMS, Celgene, Novartis, Janssen, Takeda; consulting or advisory role: AMGEN, BMS, Celgene, Juno, Janssen, Adaptive, Sanofi, Takeda; research funding: AMGEN, Celgene, Sanofi, Janssen; CK: no COI. MMu: honoraria: Janssen, BMS, Takeda, Celgene, Amgen; consulting or advisory role: Janssen, BMS, Takeda, Celgene, Amgen; research funding: BMS; travel, accommodations, expenses: Janssen, BMS, Takeda, Amgen. HWL: no COI. MMe: consulting or advisory role: Amgen, Takeda; research funding: Takeda; travel, accommodations, expenses: Celgene, AMGEN, Takeda, AbbVie, Janssen. DH: consulting or advisory role: I. Lamkap Bio AG. Discoveric AG; research funding: Celgene AG. Sanofi. Engmab AG; travel, accommodations, expenses: Celgene. AJ: no COI. AS: consulting or advisory role: I. Lamkap Bio AG. Discoveric AG; research funding: Celgene AG. Sanofi. Engmab AG. SL: no COI. SS: no COI. SF: consulting or advisory role: Sanofi, BMS, Amgen. PB: consulting or advisory role: BMS, AMGEN, Roche, MSD; research funding: BMS; travel, accommodations, expenses: BMS. AE: consulting or advisory role: Amgen; travel, accommodations, expenses: Janssen, Amgen. MG: no COI. HB: no COI. MHo: honoraria: MSD. MSR: honoraria: Celgene, BMS, Novartis, Janssen, Takeda; consulting or advisory role: Celgene, BMS, Novartis, Janssen, Takeda; research funding: Celgene, Novartis, AMGEN; travel, accommodations, expenses: Janssen, BMS, Takeda. IWB: research funding: Celgene, BMS, Janssen. MHä: honoraria: Novartis, Amgen, Roche, Takeda; consulting or advisory role: Celgene. AB: no COI. HJS: honoraria: Celgene, Janssen, Cilag; travel, accommodations, expenses: Celgene, Janssen, Cilag. HG: honoraria: Amgen, BMS, Celgene, Chugai, Janssen, Novartis, Takeda; consulting or advisory role: Amgen, BMS, Celgene, Chugai, Janssen, Novartis, Takeda; speakers bureau: Amgen, BMS, Celgene, Janssen, Novartis, Takeda; research funding: Amgen, BMS, Celgene, Chugai, Janssen, Novartis, Takeda; travel, accommodations, expenses: BMS, Celgene, Janssen, Novartis, Takeda.
